Cargando…

Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent

The epidermal growth factor receptor (EGFR) family has been validated as a successful antitumor drug target for decades. Known EGFR inhibitors were exposed to distinct drug resistance against the various EGFR mutants within non-small-cell lung cancer (NSCLC), particularly the T790M mutation. Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Wei, Ning, Jin-Feng, Meng, Qing-Wei, Hu, Jing, Zhao, Yan-Bin, Liu, Chao, Cai, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517520/ https://www.ncbi.nlm.nih.gov/pubmed/26229444 http://dx.doi.org/10.2147/DDDT.S85357

Ejemplares similares

Synthesis and Discovery of Ligustrazine–Heterocycle Derivatives as Antitumor Agents
por: Ma, Shitang, et al.
Publicado: (2022)

Pockets as structural descriptors of EGFR kinase conformations
por: Hasenahuer, Marcia Anahi, et al.
Publicado: (2017)

Correction: Pockets as structural descriptors of EGFR kinase conformations
por: Hasenahuer, Marcia Anahi, et al.
Publicado: (2018)

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
por: Diaz, Roque, et al.
Publicado: (2010)

Discovery of Novel Quinazoline Derivatives as Potent Antitumor Agents
por: Niu, Zhenxi, et al.
Publicado: (2022)

Drug repurposing: Discovery of troxipide analogs as potent antitumor agents
por: Lu, Nan, et al.
Publicado: (2020)

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
por: Wang, Aoli, et al.
Publicado: (2016)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Critical roles for EGFR and EGFR–HER2 clusters in EGF binding of SW620 human carcinoma cells
por: Wollman, Adam J. M., et al.
Publicado: (2022)

Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent
por: Xu, Qifu, et al.
Publicado: (2020)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model
por: Nakayama, Akiko, et al.
Publicado: (2013)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Discovery and SAR Study of Quinoxaline–Arylfuran Derivatives as a New Class of Antitumor Agents
por: Fan, Dongmei, et al.
Publicado: (2022)

Inertial Pocket Navigation System: Unaided 3D Positioning
por: Munoz Diaz, Estefania
Publicado: (2015)

AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer
por: Jhaveri, Teraneh Z., et al.
Publicado: (2015)

Identification of Potential Small Molecule Binding Pockets on Rho Family GTPases
por: Ortiz-Sanchez, Juan Manuel, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells
por: Chu, B, et al.
Publicado: (2015)

Synthesis, Cytotoxicity, DNA Binding and Apoptosis of Rhein-Phosphonate Derivatives as Antitumor Agents
por: Ye, Man-Yi, et al.
Publicado: (2013)

Protein Binding Pocket Optimization for Virtual High-Throughput Screening (vHTS) Drug Discovery
por: Gazgalis, Dimitris, et al.
Publicado: (2020)

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285
por: Takagi, Shinji, et al.
Publicado: (2014)

Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer
por: Zhang, Tongtong, et al.
Publicado: (2016)

The chemical diversity and structure-based discovery of allosteric modulators for the PIF-pocket of protein kinase PDK1
por: Xu, Xinyuan, et al.
Publicado: (2019)

Predicting small molecule binding pockets on diacylglycerol kinases using chemoproteomics and AlphaFold
por: Mendez, Roberto, et al.
Publicado: (2023)

Heading Estimation for Indoor Pedestrian Navigation Using a Smartphone in the Pocket
por: Deng, Zhi-An, et al.
Publicado: (2015)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer
por: Wang, Junxiong, et al.
Publicado: (2016)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket
por: Grzesiek, Stephan, et al.
Publicado: (2022)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
por: Park, Jin H., et al.
Publicado: (2012)

Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation
por: Liu, Wei, et al.
Publicado: (2023)

Druggable Transient Pockets in Protein Kinases
por: Umezawa, Koji, et al.
Publicado: (2021)

Salmonella as an Innovative Therapeutic Antitumor Agent
por: Chang, Wen-Wei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fdcht5b5s8h0si6foa6dgpu4bq